Skip to content

NEWGLAB Pharma

Metabolic Anti-Cancer Therapeutics

Menu

Home
Core Technology
Products
R & D
PR Center
- News
- Media
- Book
- Notice
Contact Us

Slide Anything Popup Preview

You are here: NEWGLAB Pharma > Slide Anything Popup Preview

[slide-anything id=’1037′]

News

FDA Approval Granted to Begin Clinical Trial
26 January 2022
FDA Approval Granted to Begin Clinical Trial KoDiscovery, LLC and NewG Lab Pharma, LLC have submitted the …Read more
Three New KOfactor 1 Advanced Products Are Now Available
26 January 2022
Three New KOfactor 1 Advanced Products Are Now Available Dr. Ko has further enhanced the …Read more
Orphan drug designation (ODD) for “treatment of stage IIb-IV melanoma” by FDA
6 May 2020
Orphan drug designation (ODD) for “treatment of stage IIb-IV melanoma” by FDA As of May …Read more

PR Center

book
media
news

United States

NEWGLAB PHARMA, INC.
Address: 701E. Pratt Street, Baltimore, MD 21202
Office: (+1) 443-887-4080
Lab: (+1) 443-887-4081
Fax: (+1) 410-234-8896
Email: contact@newglabpharma.com
Website: www.newglabpharma.com

Korea

NEWGLAB PHARMA KOREA Co., Ltd.
Address: 13F, 479, Bongeunsa-ro, Gungnam-gu, Seoul, Korea (06095)
Email: contact@newglabpharma.com
Website: www.newglabpharma.com

Recent News

FDA Approval Granted to Begin Clinical Trial
26 January 2022
Three New KOfactor 1 Advanced Products Are Now Available
26 January 2022
Orphan drug designation (ODD) for “treatment of stage IIb-IV melanoma” by FDA
6 May 2020
Acquired ODD status and License-In for additional Indications
27 April 2020
Dietary supplement sales contract with KoDiscovery and Sales started in March
27 April 2020

Suggested Links

Original website
Kofactor store

Visitors Counter

485008

Copyright © 2024 NEWGLAB Pharma. All rights reserved. Website made by Piotr Ułaszewski.

Contact Us